KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Total Debt (2016 - 2025)

Gsk (GSK) has 8 years of Total Debt data on record, last reported at $21.7 billion in Q4 2024.

  • For Q4 2024, Total Debt fell 2.93% year-over-year to $21.7 billion; the TTM value through Dec 2024 reached $21.7 billion, down 2.93%, while the annual FY2024 figure was $21.6 billion, 3.54% down from the prior year.
  • Total Debt reached $21.7 billion in Q4 2024 per GSK's latest filing, down from $22.3 billion in the prior quarter.
  • Across five years, Total Debt topped out at $22.3 billion in Q4 2023 and bottomed at $4.6 billion in Q4 2022.
  • Average Total Debt over 4 years is $15.1 billion, with a median of $16.7 billion recorded in 2021.
  • Peak YoY movement for Total Debt: tumbled 60.56% in 2022, then skyrocketed 382.09% in 2023.
  • A 4-year view of Total Debt shows it stood at $11.8 billion in 2021, then crashed by 60.56% to $4.6 billion in 2022, then surged by 382.09% to $22.3 billion in 2023, then dropped by 2.93% to $21.7 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Total Debt were $21.7 billion in Q4 2024, $22.3 billion in Q4 2023, and $4.6 billion in Q4 2022.